. Therefore, the maintenance of the subtle levels of bradykinin as well as natriuretic peptides. Even though first results of both preclinical and clinical studies indicate endothelial balance is crucial for the prevention and that combined inhibition of ACE and NEP by vasopeptidase treatment of cardiovascular disease.
Since effects of endothelium-derived substances are not (NEP) . Similar to ACE, NEP is an endothelial cell surface metallimited to vasoconstriction or vasodilatation, but may also loproteinase that is involved in the degradation of several regulatory peptides, including the natriuretic peptides, and, thus, include regulation of mitogenesis, endothelial dysfunc-NEP inhibition augments vasodilatation and natriuresis through tion not only affects the function of the cardiovascular increased levels of atrial natriuretic peptide (ANP). By inhibsystem, but also its structure. In fact, some endothelial iting the RAS and potentiating the natriuretic peptide system substances stimulate the production of cytokines and at the same time, combined NEP/ACE inhibitors, the so-called growth factors, leading to vascular smooth muscle cell vasopeptidase inhibitors, reduce vasoconstriction and enhance vasodilatation, thereby decreasing peripheral vascular resisproliferation. Thus, the balance of vasoactive peptides tance and blood pressure. Within the vessel wall this may lead to warrants an appropriate adaptation of vascular tone and a reduction of vasoconstrictor and proliferative mediators, such regulates oxidative, proliferative, and inflammatory proas angiotensin II and endothelin-1, and may increase local cesses (Fig. 1) . Therefore, the maintenance of the subtle levels of bradykinin as well as natriuretic peptides. Even though first results of both preclinical and clinical studies indicate endothelial balance is crucial for the prevention and that combined inhibition of ACE and NEP by vasopeptidase treatment of cardiovascular disease.
inhibitors represents a promising strategy in the treatment of hypertension and heart failure, angioedema occurs more frequently on vasopeptidase inhibition as compared to ACE inhi-
ACE INHIBITION AND NEP INHIBITION:
bition. To establish vasopeptidase inhibition as a novel option
THE COMPONENTS OF
in the treatment of cardiovascular disease, further validation
VASOPEPTIDASE INHIBITION
of efficacy and safety of this promising therapeutic principle is mandatory.
The beneficial effect of ACE inhibition has been documented in many large randomized trials for the treatment of hypertension [2] , after myocardial infarction, and in The importance of the renin-angiotensin-aldosterone heart failure. The Heart Outcomes Prevention Evaluasystem (RAS) in the pathophysiology of endothelial dystion (HOPE) study confirmed that ACE inhibitors are function, which represents an early stage of cardiovascuvasoprotective, independent of their effects on blood lar damage, is illustrated by numerous trials which dempressure and remodeling [3] . In addition, in patients with onstrate improvement of endothelial function [1] , and coronary artery disease, improvement of endothelial even reduction of clinical end points, using agents that function by ACE inhibition could be demonstrated angiinterrupt this system. The RAS plays a crucial role in ographically in the Trial on Reversing Endothelial Dyscardiovascular regulation both as a circulating and parafunction (TREND), particularly in patients with high crine local vascular system. The endothelium is a source serum cholesterol who are prone to severe endothelial dysfunction [1] . The mechanisms involved may be related to inhibitory effects on angiotensin formation vasoconstrictor with proliferative properties, but also inincluding renovascular hypertension, spontaneous hycrease the local concentration of bradykinin. In turn, the pertension [4, 5], deoxycorticosterone acetate-induced production of NO and prostacyclin, which may contribhypertension [5], as well as salt-sensitive hypertension ute to the vascular protective effects of ACE inhibitors [6, 7] . In spontaneously hypertensive rats, vasopeptidase by vasopeptidase inhibition, by improving local blood inhibition significantly lowered blood pressure, even flow, and preventing platelet activation. As a principle when combined with experimental diabetes [4] . Since of vasopeptidase inhibition, beneficial effects of ACE antihypertensive effects of combined ACE/NEP inhibiinhibition are combined with the additional inhibition tion exceeded those of ACE inhibition alone, and reof the neutral endopeptidase (NEP).
sulted in additional improvement of endothelial function Selective NEP inhibition prevents the degradation of to a greater extent than attributable to lowering of blood vasoactive peptides such as ANP, BNP, CNP, substance pressure [6, 8] , vasopeptidase inhibition may advance as P, and bradykinin, and increases their biologic activity. a promising novel option for the treatment of various This implicates that simultaneous inhibition of ACE and forms of hypertension. NEP may exceed the effects of inhibiting either system
In salt-sensitive Dahl rats omapatrilat, as compared alone. Therefore, compounds with the capability of inwith equipotent doses of the ACE inhibitor captopril, hibiting ACE and NEP at the same time may offer the restored the impaired NO system by increasing protein possibility to inhibit the RAS and to potentiate the natrilevels of endothelial NO synthase and vascular nitrate uretic peptide system by the use of one single molecule, levels, and normalized endothelium-dependent relaxand, thus, may simultaneously reduce vasoconstriction ations [6] . Since endothelial dysfunction is not only the and enhance vasodilatation. Correspondingly, a number result, but also initiator as well as promoter of cardiovasof substances with affinities for both ACE and NEP are cular disease, vasopeptidase inhibition may be beneficial currently under development. Among those so-called in interrupting the vicious cycle of altered endothelial "vasopeptidase inhibitors," omapatrilat is the compound function. for which most preclinical and clinical data are presently available.
VASOPEPTIDASE INHIBITORS IN THE TREATMENT OF HYPERTENSION VASOPEPTIDASE INHIBITORS IN EXPERIMENTAL HYPERTENSION
Vasopeptidase inhibitors have been shown to be welltolerated and effective in clinical trials on hypertensive Vasopeptidase inhibition has been shown to lower blood pressure under various experimental conditions, patients under several conditions. In 63 patients with
S-56
salt-sensitive hypertension, 40 mg/day of omapatrilat reThe plasma concentrations of omapatrilat administered vealed a greater reduction in systolic, diastolic, and in to 29 patients with moderate to severe renal impairment, mean arterial pressure as compared to 20 mg/day of and even in patients on hemodialysis treatment, did not lisinopril [9] . In a study on 690 patients with mild to differ between the control and those patients with normoderate hypertension, omapatrilat (5 to 40 mg/day) mal renal function [13] . Therefore, no dose adjustment lowered systolic blood pressure (sBP) a much greater of omapatrilat is required in patients with renal impairextent than lisinopril (20 to 40 mg/day). However, comment, independent of its severity. In addition, even in pared with studies of other antihypertensive drugs, such patients with impaired renal function, omapatrilat inas ACE inhibitors, the number of patients treated with creased urinary ANP excretion [14, 15] , indicating the vasopeptidase inhibitors at present is rather small. presence of its beneficial properties irrespective of the Therefore, a large-scale clinical trial with 12,600 padegree of renal impairment. tients, Omapatrilat in Persons with Enhanced Risk of Atherosclerosis (OPERA), was initiated to evaluate the SAFETY OF VASOPEPTIDASE INHIBITORS impact of vasopeptidase inhibition in isolated systolic hypertension [10] . Patients older than 65 years with sBP Vasopeptidase inhibitors have been used over a broad between 140 and 160 mm Hg will be randomized in 900 range of dosages, but the number of patients treated centers to receive either 40 mg/day of omapatrilat or and documented at present is still rather low. In clinical placebo, and cardiovascular morbidity and mortality will studies, side effects were comparable to those of ACE be followed up for 3 to 5 years. Another clinical trial with inhibitors. Cough and flush in 573 patients in the Inhibi-25,267 hypertensive patients, the Omapatrilat Cardiovastion of Metalloproteinase in a Randomized Exercise and cular Treatment Assessment Versus Enalapril (OCTAVE) Symptoms Study in Heart Failure (IMPRESS) trial were trial, to assess the efficacy and safety of low doses (10 reported to occur equally often with ACE inhibitor treatmg/day) of omapatrilat versus 5 mg/day of enalapril has ment [16] . Similarity of adverse effects of ACE inhibition recently been completed and preliminary results were and vasopeptidase inhibition were recently confirmed in presented in March 2002. These data indicate that in all 5770 patients in the Omapatrilat Versus Enalapril Ransubgroups, omapatrilat was capable of lowering sBP and domized Trial of Utility in Reducing Events (OVERdBP after 8 and 24 weeks of treatment, respectively, to TURE) trial [17] . Nevertheless, in data submitted for a greater extent when compared to enalapril.
the new drug application of omapatrilat to the US Food and Drug Administration (FDA), 44 instances of angioedema were reported among more than 6600 patients VASOPEPTIDASE INHIBITORS AND
[18]. Therefore, the incidence of angioedema reported THE KIDNEY in the Heart Outcomes Prevention Evaluation (HOPE) Because inhibition of ANP degradation seems to be study [3] was about twice as high (0.7%) as on treatment one of the most important features of vasopeptidase with ramipril. Since patients in the IMPRESS and inhibitors, and elevation of plasma ANP levels by vaso-OVERTURE trial were pretreated with ACE inhibitors, peptidase inhibition has been demonstrated in several elevated incidence of angioedema after the onset of vasopreclinical [6] and clinical studies, there is a strong link peptidase inhibition requires even more careful evaluato renal involvement in the regulatory processes induced tion in large scale, randomized, double-blind clinical triby vasopeptidase inhibition.
als. The OCTAVE study was especially designed to Since renal protection, such as in diabetic nephropaevaluate the risk of adverse effects on omapatrilat treatthy, is one of the favorable effects of ACE inhibitors, the ment in low doses. Preliminary data of the OCTAVE influence of vasopeptidase inhibitors on renal function is study released in March 2002 indicate that in the treatof major interest. In experimental diabetes, vasopeptiment of hypertension, omapatrilat is indeed efficient and dase inhibition reduced albuminuria and led to improvesafe. Although all other adverse effects occurred with ment of renal function [4] . In 89 patients with impaired comparable frequency, angioedema presented with a renal function (creatinine clearance Ͻ60 mL/min), 12 threefold higher incidence in patients treated with a vaweeks treatment with omapatrilat reduced proteinuria sopeptidase inhibitior as compared to patients on ACE by about 20% and increased serum creatinine by about inhibitors (2.17% vs. 0.68%, respectively). Thus, an in-15%, thus indicating improvement of renal function by creased incidence of angioedema appears to be associvasopeptidase inhibition. Meanwhile, vasopeptidase inated with simultaneous inhibition of NEP and ACE, and hibition has been proven to slow the progression of renal it may be speculated that its occurrence is linked to injury in subtotally nephrectomized rats [11, 12] . the decreased degradation of bradykinin. Since patients Since renal impairment is a frequent condition among were treated for 24 weeks only in the OCTAVE study, patients with advanced cardiovascular disease, safety of pharmacotherapy in these patients is an important issue.
safety of vasopeptidase inhibitors remains a matter of heart failure. To replace or extend traditional treatment
